Amgen Inc (AMGN)
283.61
-12.32
(-4.16%)
USD |
NASDAQ |
Nov 15, 16:00
283.55
-0.06
(-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 152.45B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 7.01% |
| Valuation | |
| PE Ratio | 36.31 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.701 |
| Price to Book Value | 20.25 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 2.25 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 8.024 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 24.86% |
Profile
| Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio. |
| URL | https://www.amgen.com |
| Investor Relations URL | https://investors.amgen.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | Nov. 18, 2024 |
| Last Ex-Dividend Date | Aug. 16, 2024 |
Ratings
Profile
| Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio. |
| URL | https://www.amgen.com |
| Investor Relations URL | https://investors.amgen.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | Nov. 18, 2024 |
| Last Ex-Dividend Date | Aug. 16, 2024 |